Optimal approach to prevent veno-occlusive disease following hematopoietic stem cell transplantation in children

Pediatric Transplantation

Volumn 14, Issue 6, 2010, Pages 683-687

  Hassan, Zuzana ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEFIBROTIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GEMTUZUMAB OZOGAMICIN; GLUTAMINE; HEPARIN; L SELECTIN; LOW MOLECULAR WEIGHT HEPARIN; MATRIX METALLOPROTEINASE; MELPHALAN; MERCAPTOPURINE; NITRIC OXIDE; NONESSENTIAL AMINO ACID; OXALIPLATIN; PENTOXYFILLINE; PLASMINOGEN ACTIVATOR INHIBITOR; PROSTAGLANDIN E1; PYRROLIZIDINE ALKALOID; THROMBOMODULIN; TIOGUANINE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; XANTHINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ALBUMIN BLOOD LEVEL; ASCITES; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG MECHANISM; DRUG WITHDRAWAL; EDITORIAL; FLUID RETENTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; INCIDENCE; JAUNDICE; LIVER BIOPSY; LIVER DISEASE; LIVER INJURY; LIVER PROTECTION; LIVER SINUSOID; LIVER VEIN OBSTRUCTION; PATHOPHYSIOLOGY; PORTAL VEIN BLOOD FLOW; PROPHYLAXIS; PROTEIN BLOOD LEVEL; SINUSOIDAL OBSTRUCTION SYNDROME; THROMBOCYTOPENIA; TOXICITY; UMBILICAL VEIN; WEIGHT GAIN;

CHOLAGOGUES AND CHOLERETICS; FIBRINOLYTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; POLYDEOXYRIBONUCLEOTIDES; RISK FACTORS; URSODEOXYCHOLIC ACID;

EID: 77955834416     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01311.x     Document Type: Editorial

References (42)

1. Deleve LD, Shulman HM, Mcdonald GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002 : 22 : 27 42.
2. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993 : 118 : 255 267.
3. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984 : 4 : 116 122.
4. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987 : 44 : 778 783.
5. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995 : 85 : 3005 3020.
6. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008 : 41 : 229 237.
7. Helmy A. Review article: Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther 2006 : 23 : 11 25.
8. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998 : 92 : 3599 3604.
9. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003 : 102 : 1578 1582.
10. Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998 : 92 : 4568 4572.
11. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998 : 128 : 975 981.
12. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000 : 64 : 32 38.
13. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002 : 100 : 1977 1983.
14. Park SH, Lee MH, Lee H, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002 : 29 : 137 143.
15. Thornley I, Lehmann LE, Sung L, et al. A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2004 : 10 : 635 644.
16. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007 : 13 : 206 217.
17. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 1992 : 79 : 2834 2840.
18. Marsa-Vila L, Gorin NC, Laporte JP, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991 : 47 : 346 354.
19. Or R, Nagler A, Shpilberg O, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996 : 61 : 1067 1071.
20. Reiss U, Cowan M, Mcmillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: Incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002 : 24 : 746 750.
21. Rosenthal J, Sender L, Secola R, et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996 : 18 : 185 191.
22. Simon M, Hahn T, Ford LA, et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: Possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001 : 27 : 627 633.
23. Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: A systematic review and meta-analysis. Bone Marrow Transplant 2006 : 37 : 677 686.
24. Gluckman E, Jolivet I, Scrobohaci ML, et al. Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation. Nouv Rev Fr Hematol 1990 : 32 : 1 3.
25. Bearman SI, Shen DD, Hinds MS, Hill HA, Mcdonald GB. A phase III study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 1993 : 84 : 724 730.
26. Lee SH, Yoo KH, Sung KW, et al. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: Incidence, risk factors, and outcome. Bone Marrow Transplant 2009 : advance online publication, 14 December 2009; doi :.
27. Song JS, Seo JJ, Moon HN, Ghim T, Im HJ. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. J Korean Med Sci 2006 : 21 : 897 903.
28. Morabito F, Gentile M, Gay F, et al. Insights into defibrotide: An updated review. Expert Opin Biol Ther 2009 : 9 : 763 772.
29. Corbacioglu S, Honig M, Lahr G, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006 : 38 : 547 553.
30. Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004 : 103 : 1968.
31. Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004 : 10 : 347 354.
32. Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: Minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007 : 40 : 79 82.
33. Attal M, Huguet F, Rubie H, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective, randomized trial. Blood 1993 : 82 : 732 736.
34. Clift RA, Bianco JA, Appelbaum FR, et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993 : 82 : 2025 2030.
35. Brown SA, Goringe A, Fegan C, et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 1998 : 22 : 281 284.
36. Bearman SI, Lee JL, Baron AE, Mcdonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997 : 89 : 1501 1506.
37. Lakshminarayanan S, Sahdev I, Goyal M, Vlachos A, Atlas M, Lipton JM. Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution. Pediatr Transplant 2010.
38. Bajwa RP, Cant AJ, Abinun M, et al. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: Effectiveness and a scoring system for initiating treatment. Bone Marrow Transplant 2003 : 31 : 591 597.
39. Peres E, Kintzel P, Dansey R, et al. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease. Blood Coagul Fibrinolysis 2008 : 19 : 203 207.
40. Goringe AP, Brown S, O'callaghan U, et al. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant 1998 : 21 : 829 832.
41. Ringden O, Remberger M, Lehmann S, et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2000 : 25 : 993 996.
42. Al Beihany A, Al Omar H, Sahovic E, et al. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant 2008 : 41 : 287 291.